• Wondering if Teladoc Health's current share price reflects its true worth, or if the market is still pricing in old expectations.
• The stock last closed at US$6.46, with returns of 12.3% over 7 days and 22.6% over 30 days. The year to date return is an 8.4% decline and the 1 year return is an 8.5% decline alongside deeper multi year losses.
• Recent coverage has focused on Teladoc Health's position in virtual care and the broader sentiment around telehealth providers. This helps explain the sharp shorter term share price moves against a weak multi year backdrop. Investors are weighing up how its current business profile, balance sheet, and market perception line up with what they are paying per share today.
• On Simply Wall St's valuation checks, Teladoc Health scores 5 out of 6. Next is a closer look at what different valuation methods say about that score and how a broader view of value could give you a clearer picture by the end of this article.

Approach 1: Teladoc Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting the cash it may generate in the future and discounting those cash flows back to the present.

For Teladoc Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is about US$148.1 million. Analysts provide explicit free cash flow estimates only for the next few years, and Simply Wall St then extrapolates further, with projected free cash flow of US$176.1 million in 2030 and a series of annual figures between 2026 and 2035.

Discounting those projected cash flows back to today gives an estimated intrinsic value of US$12.07 per share. Compared with the recent share price of US$6.46, the model implies Teladoc Health trades at a 46.5% discount to this intrinsic value, which points to the stock looking undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Teladoc Health is undervalued by 46.5%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Teladoc Health Price vs Sales

For companies where earnings are limited or volatile, the P/S ratio can be a useful way to compare what investors are paying for each dollar of revenue. A higher or lower P/S is often linked to expectations for future growth and the level of risk investors are willing to accept, so there is no single “right” number in isolation.

Teladoc Health currently trades on a P/S of 0.46x. This sits well below the Healthcare Services industry average P/S of 2.19x and also below the peer group average of 2.23x. On these simple comparisons, the shares look cheap relative to both the sector and peers.

Simply Wall St also calculates a proprietary “Fair Ratio” of 1.95x for Teladoc Health. This is designed to be more tailored than a straight peer or industry comparison because it takes into account factors such as the company’s earnings profile, growth outlook, profit margins, market cap and risk characteristics. When comparing the Fair Ratio of 1.95x with the current P/S of 0.46x, the shares screen as materially below that fair range on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Teladoc Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a simple way to attach a story about Teladoc Health to the numbers you think are reasonable for future revenue, earnings and margins. You can then link that story to a Fair Value that you can compare with the current share price to help assess whether the stock looks appealing or stretched.

On Simply Wall St's Community page, Narratives are set up so you can pick or build a view. For example, one investor might lean toward a higher Fair Value around US$10.50 based on expectations for BetterHelp's insurance shift and margin recovery. Another might anchor closer to US$5.00 if more cautious about competition and reimbursement. The platform then keeps those Fair Values updated as new earnings, guidance or news arrive, so your decision making stays tied to fresh information rather than a static snapshot.

For Teladoc Health, however, we'll make it really easy for you with previews of two leading Teladoc Health Narratives:

Fair value in this bullish narrative: US$10.50 per share.

Current price vs this fair value implies the shares trade about 38.5% below that estimate using the DCF style assumptions behind the narrative.

Revenue growth assumption in this view: 2.23% a year.

• BetterHelp's insurance shift and a broader virtual care platform are expected to support margin recovery and a higher quality revenue mix over time.
• International expansion and AI supported care coordination feature as key drivers for higher engagement, lower churn and more diversified revenue.
• This narrative leans on the higher end of analyst price targets, assumes earnings progress toward US$62.8m by 2029, and uses a higher future P/E multiple of 42.7x with a 10.84% discount rate.

Fair value in this bearish narrative: US$5.00 per share.

Current price vs this fair value implies the shares trade about 29.2% above that estimate based on the more cautious earnings and discount rate assumptions.

Revenue growth assumption in this view: 0.76% decline a year.

• Rising compliance costs, reimbursement uncertainty and competition are treated as ongoing headwinds for margins and long term profitability.
• Limits on digital infrastructure and health access in some markets, plus pressure on BetterHelp's economics as insurance use grows, are seen as constraints on revenue upside.
• This narrative aligns with the lower end of analyst targets, uses a fair value of US$5.00, assumes a future profit margin of about 6.0% and applies an 8.6x future P/E with an 11.15% discount rate.

These two narratives bracket a range of views on Teladoc Health, so the next step is to decide which set of assumptions, risks and valuation inputs you are more comfortable with and how that fits alongside other holdings in your portfolio.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Teladoc Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Teladoc Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.